Pluri (PLUR) EBITDA (2010 - 2025)
Pluri (PLUR) posted quarterly EBITDA of -$6.5 million for Q4 2025, down 31.25% year-over-year from -$9.5 million in Q4 2024, and down 2.46% quarter-over-quarter from -$6.4 million in Q3 2025.
Pluri (PLUR) EBITDA (2010 - 2025) Analysis & Trends
Pluri (PLUR) has reported EBITDA for 16 consecutive years, with -$6.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, EBITDA fell 31.25% year-over-year to -$6.5 million; the TTM figure through Dec 2025 stood at -$24.9 million (down 14.52% YoY), while the FY2025 annual figure was -$22.2 million, changed 0.08% from the prior year.
- EBITDA declined to -$6.5 million in Q4 2025 per PLUR's latest filing, from -$6.4 million in the prior quarter.
- Across five years, EBITDA topped out at -$5.0 million in Q4 2024 and bottomed at -$14.6 million in Q2 2021.
- Historically, EBITDA has averaged -$7.7 million across 5 years, with a median of -$6.6 million in 2023.
- Annual changes were most pronounced in 2021 — EBITDA plunged 92.26% — and 2022, when it soared 39.49%.
- Pluri's EBITDA stood at -$10.8 million in 2021, then surged by 38.13% to -$6.7 million in 2022, then advanced by 21.95% to -$5.2 million in 2023, then climbed by 4.91% to -$5.0 million in 2024, then tumbled by 31.25% to -$6.5 million in 2025.
- Business Quant data shows PLUR's EBITDA at -$6.5 million in Q4 2025, -$6.4 million in Q3 2025, and -$6.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.53 Bn | 130.68 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.34 Bn | 78.35 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.67 Bn | 59.48 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.94 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.78 Bn | 27.47 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.81 Bn | 9.42 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.21 Bn | 26.05 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 26.99 Bn | 26.15 Bn | - | 133.12 Mn |
| 10 | Pluri | 15.74 Mn | 3.26 Mn | 86,000.00 | -6.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.51 Mn |
| Sep 30, 2025 | -6.35 Mn |
| Jun 30, 2025 | -6.62 Mn |
| Mar 31, 2025 | -5.40 Mn |
| Dec 31, 2024 | -4.96 Mn |
| Sep 30, 2024 | -5.20 Mn |
| Jun 30, 2024 | -6.03 Mn |
| Mar 31, 2024 | -5.53 Mn |
| Dec 31, 2023 | -5.21 Mn |
| Sep 30, 2023 | -5.38 Mn |
| Jun 30, 2023 | -6.54 Mn |
| Mar 31, 2023 | -7.10 Mn |
| Dec 31, 2022 | -6.68 Mn |
| Sep 30, 2022 | -6.92 Mn |
| Jun 30, 2022 | -8.88 Mn |
| Mar 31, 2022 | -10.48 Mn |
| Dec 31, 2021 | -10.80 Mn |
| Sep 30, 2021 | -11.44 Mn |
| Jun 30, 2021 | -14.59 Mn |
| Mar 31, 2021 | -14.23 Mn |